anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tapentadol is a centrally-acting synthetic analgesic. It is 18 times less potent than morphine in binding to the human mu-opioid receptor and is 2–3 times less potent in producing analgesia in animal models. Tapentadol has been shown to inhibit norepinephrine reuptake in the brains of rats resulting in increased norepinephrine concentrations. In preclinical models, the analgesic activity due to the mu-opioid receptor agonist activity of tapentadol can be antagonized by selective mu-opioid antagonists (e.g., naloxone), whereas the norepinephrine reuptake inhibition is sensitive to norepinephrine modulators. Tapentadol exerts its analgesic effects without a pharmacologically active metabolite.

Effects on the cardiovascular system: There was no effect of therapeutic and supratherapeutic doses of tapentadol on the QT interval. In a randomized, double-blind, placebo- and positive-controlled crossover study, healthy subjects were administered five consecutive doses of NUCYNTA™ 100 mg every 6 hours, NUCYNTA™ 150 mg every 6 hours, placebo and a single oral dose of moxifloxacin. Similarly, NUCYNTA™ had no relevant effect on other ECG parameters (heart rate, PR interval, QRS duration, T-wave or U-wave morphology).
Each data collection tool was collected as in the experimental group patients, but without breathing exercises. Only routine nursing care was given to the patients in the control group. The patients in the control group were given a breathing exercise brochure/booklet when they came to the control after the postoperative 30th day, and they were shown how the breathing exercises would be done correctly.
Mastectomy is associated with significant acute postoperative pain. It has been shown that inadequately managed post-mastectomy pain in breast cancer patients can have detrimental physiological, psycho-behavioural, recovery and healthcare utilization consequences. Most significantly, acute postoperative pain appears to be a substantial risk factor for progression to chronic post-surgical pain (CPSP), occurring in up to 68% of patients,, with higher severity of acute pain being linked with a greater progression to CPSP. A multimodal analgesic approach is the optimal method of reducing the risk of progression to CPSP, and there are a number of analgesic techniques that can be used to reduce the incidence of acute postoperative pain. Of the analgesic techniques used, the most common are multimodal systemic analgesia, thoracic paravertebral blockade, thoracic epidural analgesia, local anesthetic wound infiltration, and more recently pecs blocks and serratus plane blocks. The former three techniques are all associated with drawbacks including technical challenges, high risk of adverse effects, and limited evidence to minimize the progression to CPSP states, whilst local anesthetic wound infiltration has highly variable pain outcomes. Therefore, an alternative, safer, and more effective technique would be ideal.

Local infiltration analgesia (LIA) techniques have been demonstrated to be efficacious in joint surgery, whilst injection of local anesthesia in the serratus plane to target some of the intercostal and pectoral nerves may have some benefit in mastectomy surgery. However, nobody has yet performed LIA around these nerves in breast surgery, and the investigators feel that this has enormous potential.
Allogeneic stem cell transplantation is a life saving procedure in selected high-risk or recurrent hematologic malignancies and marrow failure syndromes. However its wide application is limited by availability of suitably HLA matched adult donors. Umbilical Cord Blood (UCB) has been increasingly used as an alternative hematopoietic stem cell source for these patients. To date, over 10,000 UCB transplants have been performed in both children32-38 and adults.35,39-44 Its advantages include easier procurement, decreased risk to donors, reduced risk of transmitting infections, the immediate availability of cryopreserved units, and acceptable HLA mismatches. The transplantation of UCB allows a greater degree of HLA mismatching without an unacceptably high incidence of graft versus host disease (GVHD). Adult patients receiving myeloablative cord blood transplants have a 90% chance of engraftment, but carry a 50% rate of transplant related mortality.
This trial was designed as an open, single-arm, multicenter, dose-increasing trial. three dose groups (0.3×10\^5/kg, 1×10\^5/kg, 3×105/kg) are set up, starting from the low dose group to explore the safe and effective dose.
This study was planned as a randomized controlled experimental study in order to evaluate the effectiveness of Isolation Training Given to Caregivers of Isolated Sick Individuals with Different Methods. The universe of the research will be the caregivers of the patients isolated in the intensive care and services of the Beykent University hospital, and the sample will be the caregivers of the patients whose hemodynamics are stable and willing to work. Sampling criteria; the patient's hemodynamics is stable, and the patients and their caregivers are willing to work. Power analysis was performed for the sample size of the study and it was decided to have a total of 60 patients, 30 in each group (control group, virtual reality group). Research data; structured information form, knowledge test for Isolation Measures, skills checklist for Isolation Measures and training satisfaction survey. Study data will be analyzed with SPSS 25 statistical program.

In the research; Two different training methods will be used and these are; Virtual Glasses application, which is the experimental group; For the care and follow-up of the isolated patient, a video will be taken and watched in order to show the caregivers that the personal protective equipment is worn correctly and in order, and this is explained. This video will be rendered 3D and shown to caregivers. Afterwards, the caregiver will be expected to apply the training received. The Control Group, on the other hand, will be trained with a training booklet to be applied as a standard procedure, which provides information on isolation methods.Before these trainings, knowledge test (pretest) and after training knowledge tests (posttest) will be done. During the training, the equipment will be worn by the caregivers, and the actions that are done / not done will be evaluated by marking from the checklist prepared during this process. Finally, the satisfaction with education questionnaire will be filled.With this study, it will be ensured that the Efficiency of the Isolation Training Given to the Caregivers of Isolated Sick Individuals with Different Methods.
Chemotherapy-induced cognitive impairment (CICI) is one of the major adverse effects of antineoplastic drugs, which decrease the quality of life in cancer survivors. Extensive experimental and clinical research suggests that chemotherapeutic drugs generate an enormous amount of reactive oxygen species (ROS), contributing to oxidative stress, neuroinflammation, blood-brain barrier (BBB) disruption, and neuronal death, eventually leading to CICI. Despite the progress in exploring different pathological mechanisms of CICI, effective treatment to prevent CICI progression has not been developed yet. Nrf2 is the principal transcription factor that regulates cellular redox balance and inflammation-related gene expression. Emerging evidence suggests that upregulation of Nrf2 and its target genes could suppress oxidative stress, and neuroinflammation, restore BBB integrity, and increase neurogenesis. This review discusses the role of Nrf2 in CICI, how it responds to oxidative stress, inflammation, neurotoxicity, and potential Nrf2 activators that could be used to enhance Nrf2 activation in CICI.
Clinically, chronic pain and depression often coexist in multiple diseases and reciprocally reinforce each other, which greatly escalates the difficulty of treatment. The neural circuit mechanism underlying the chronic pain/depression comorbidity remains unclear. The present study reports that two distinct subregions in the paraventricular thalamus (PVT) play different roles in this pathological process. In the first subregion PVT posterior (PVP), glutamatergic neurons (PVPGlu) send signals to GABAergic neurons (VLPAGGABA) in the ventrolateral periaqueductal gray (VLPAG), which mediates painful behavior in comorbidity. Meanwhile, in another subregion PVT anterior (PVA), glutamatergic neurons (PVAGlu) send signals to the nucleus accumbens D1-positive neurons and D2-positive neurons (NAcD1→D2), which is involved in depression-like behavior in comorbidity. This study demonstrates that the distinct thalamo-subcortical circuits PVPGlu→VLPAGGABA and PVAGlu→NAcD1→D2 mediated painful behavior and depression-like behavior following spared nerve injury (SNI), respectively, which provides the circuit-based potential targets for preventing and treating comorbidity.
The methyltransferase Wilms' tumor 1-associated protein (WTAP) has been reported to be dysregulated in various tumors. However, its role in renal cell carcinoma (RCC) remains elusive. Here, we explored whether WTAP was upregulated in RCC specimens compared to normal tissues. Functionally, WTAP promoted RCC cell proliferation and metastasis in vivo and in vitro. Mechanistically, WTAP act as an N6-methyladenosine transferase to regulate the m6A modification of long noncoding RNA TEX41. Then, the upregulated m6A modification destabilized TEX41 in a YTHDF2-dependent manner. Furthermore, TEX41 interacted with the SUZ12 protein and increased the histone methyltransferase activity of SUZ12, resulting in HDAC1 silencing. Totally, our study demonstrated the oncogenic the role of WTAP/TEX41/SUZ12/HDAC1 axis in RCC progression.
The invention relates to a pharmaceutical composition for prevention and treatment of osteoporosis and its preparation. The pharmaceutical composition comprises dodder, or a mixture of cnidium fruit and dodder. It contains high quantity of coumarins and flavones effective components after purification. The compound medicinal compositions obtained by mixing the dodder and cnidium fruit can obviously improve the bone mineral density and the calcium and phosphor content in the bone ash. Furthermore, the oraltoxicity of the cnidium fruit is decreased. The single dodder pharmaceutical composition has an obvious effect. Moreover, the pharmaceutical composition can be used together with the calcareous material and/or vitamin D3 to enhance the effect.
Compartment syndrome is usually due to trauma but can also have atraumatic causes. It is defined as a compromise of neurovascular and muscle function that presents symptomatically with the six P's: pain, pallor, paresthesia, paralysis, poikilothermia, and pulselessness. Diagnosis is confirmed by a delta pressure of <30 mmHg (diastolic blood pressure minus the compartment pressure). This case details a 15-year-old male football player with atraumatic compartment syndrome in the lateral compartment of the right lower leg. Symptoms of swelling and pain began 2 weeks before presentation after the patient was "juked." The patient's symptoms improved after a week of rest but worsened when he returned to practice. In the emergency department, the patient was able to ambulate with pain and declined pain medication. Examination revealed severe tenderness, mildly decreased strength, decreased sensation, and edema in the lateral compartment via bedside ultrasound. Because of the concern for compartment syndrome, pressure was checked with a disposable manometer (Compass CT disposable pressure transducer) revealing a delta pressure of 26 mmHg. The patient consequently underwent fasciotomy, eventually returning to baseline function without deficits. Awareness of this atypical presentation of compartment syndrome will assist providers in making a critical diagnosis and preventing severe complications and disability. This case also demonstrates the potential of disposable pressure transducers for cost-effective and accurate diagnostic confirmation of compartment syndrome in the emergency department.
Ethambutol hydrochloride, following a single oral dose of 25 mg/kg of body weight, attains a peak of 2 to 5 mcg/mL in serum 2 to 4 hours after administration. When the drug is administered daily for longer periods of time at this dose, serum levels are similar. The serum level of ethambutol falls to undetectable levels by 24 hours after the last dose except in some patients with abnormal renal function. The intercellular concentrations of erythrocytes reach peak values approximately twice those of plasma and maintain this ratio throughout the 24 hours.

During the 24-hour period following oral administration of ethambutol approximately 50 percent of the initial dose is excreted unchanged in the urine, while an additional 8 to 15 percent appears in the form of metabolites. The main path of metabolism appears to be an initial oxidation of the alcohol to an aldehydic intermediate, followed by conversion to a dicarboxylic acid. From 20 to 22 percent of the initial dose is excreted in the feces as unchanged drug. No drug accumulation has been observed with consecutive single daily doses of 25 mg/kg in patients with normal kidney function, although marked accumulation has been demonstrated in patients with renal insufficiency.

Ethambutol diffuses into actively growing mycobacterium cells such as tubercle bacilli. Ethambutol appears to inhibit the synthesis of one or more metabolites, thus causing impairment of cell metabolism, arrest of multiplication, and cell death. No cross resistance with other available antimycobacterial agents has been demonstrated. 

Ethambutol has been shown to be effective against strains of Mycobacterium tuberculosis but does not seem to be active against fungi, viruses, or other bacteria. Mycobacterium tuberculosis strains previously unexposed to ethambutol have been uniformly sensitive to concentrations of 8 or less mcg/mL, depending on the nature of the culture media. When ethambutol has been used alone for treatment of tuberculosis, tubercle bacilli from these patients have developed resistance to ethambutol hydrochloride by in-vitro susceptibility tests; the development of resistance has been unpredictable and appears to occur in a step-like manner. No cross resistance between ethambutol and other antituberculous drugs has been reported. Ethambutol has reduced the incidence of the emergence of mycobacterial resistance to isoniazid when both drugs have been used concurrently. An agar diffusion microbiologic assay, based upon inhibition of Mycobacterium smegmatis (ATCC 607) may be used to determine concentrations of ethambutol in serum and urines.
The vast majority of children with obsessive compulsive disorder (OCD) are given serotonin reuptake inhibitor (SRI) drugs as initial treatment. However, recommended doses of these medications leave many children with clinically significant residual symptoms. Health care experts typically recommend augmenting SRI treatment with cognitive behavioral therapy (CBT), yet this recommendation is seldom followed. This study will contrast two CBT augmentation strategies to continued medication management alone: CBT administered by a psychologist and instructional CBT (I-CBT)administered by a psychiatrist in the context of ongoing medication management.

All patients in the trial will be eligible to receive a full course of CBT by study end. Participants in this study will be randomly assigned to receive CBT, I-CBT or continued medication management. All participants will continue their SRI treatment for 12 weeks. After the 12-week treatment period, participants who received I-CBT or medication management alone and who remain symptomatic will be given CBT as will participants who are asymptomatic but relapse within 6 months after treatment. Assessments will be conducted at Weeks 0, 4, 8, and 12. Follow-up assessments will be conducted at 3 and 6 months post-treatment.
The first Dutch-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from October 2014.
Patients undergo collection of blood samples on day 1 for analysis via HD-SCA fluid biopsy. Medical charts of patients are reviewed at 3 months post-biopsy or CT screening.
Group 3 will receive saracatinib at a dose determined by the response to 50mg P.O. daily, as well as dose given to group 2. Duration is 4 weeks.
This group has more than 10% risk of early onset of islet autoimmunity and can come to visits at 2, 6 and 10 years of age. At the visits blood samples are drawn and disease risk information and information about symptoms is given. The child will wear an accelerometer for one week after each visit.
Participants will receive RO7049389 (600 mg once daily \[QD\]) in addition to their background NUC therapy for the 48-week treatment period. RO7020531 (150 mg once every other day \[QOD\]) will be administered during Weeks 1-12 and Weeks 25-36. At the end of the treatment period, participants will continue NUC treatment during the follow-up unless the NUC discontinuation criteria have been met.
PURPOSE:To provide a new combination product improved in the storage stability of vitamin C and capable of being apllied to cosmetics, medicines, foods, feeds, etc. CONSTITUTION:The combination product of formula I (R1, R2 are H, CH3, CO2H; R3 is CH2, O, CO, etc.; x, y are 0-10; p, r, q, r, s, t are 0-4). For example, 3-O-benzyl-2-O-benzyloxycarbonylmethyl-L-ascorbic acid. This combination product is obtained e.g. by reacting a compound of formula II (R4 is a group capable of being released by a reducing reaction; X is Cl, Br, I) with a compound of formula III in the presence of a basic catalyst in an organic solvent, and subsequently releasing the R4 group of the obtained compound of formula IV under a reducing condition.
The invention belongs to the technical field of medical biological engineering, and relates to a novel dendritic cell (DC) vaccine preparation technology. In the technology, an hTRT (human Telomerase Reverse Transcriptase) gene is inserted into an adeno-associated virus (AAV), and mannan surface modification is performed, so that an infected DC cell can be targeted in vitro. Along with stable expression of the hTRT gene in the DC, the DC can be continuously stimulated by a large quantity of hTRT antigen peptides. An hTRT antigen is a tumor-related antigen, so that a lymphocyte stimulated by the DC vaccine almost acts strong killing effects on all tumor cells. The vaccine prepared with a method disclosed by the invention has the characteristics of strong inducting function, high safety, low price, easiness for large-scale production, wide clinical application and the like. The problems of short half-life period, low transduction efficiency and poor activation-immune effect cell ability existing in the conventional DC transfected with an in-vitro antigen peptide are solved.
The patients with stage II to III breast cancer with biopsy-confirmed nodal metastases who convert to cN0 following NAC is recruited. Eligible patients are treated with axillary sentinel or targeted lymph node biopsy alone. Post-surgery radiation therapy will be administered at the discretion of the radiologist and the nodal radiotherapy must be conducted in patients with low nodal disease.
Polymer gel dosimeters based on radiation-induced polymerization of N-(Isobutoxymethyl) acrylamide (NIBMA) polymer gels in normal atmospheric condition (NIBMAGAT) have been synthesized and studied as a new composition of polymer gel dosimeters for radiotherapy treatment planning. The dosimeters were irradiated with at absorbed doses up to 30 Gy and no change in dose response was observed even after using repeatedly for eight times. The novel composition shows no change in the relaxation rate or absorbance of the gel dosimeters up to 144 hours. Dose response of NIBMAGAT gel dosimeters increases with increase of monomer concentration. The relaxation rate of NIBMAGAT gel increases with increase of THPC concentration from 2.5 to 5 mM, but the dose response is not affected with increase of THPC concentration from 5 to 20 mM. The results show that the dose sensitivity increases significantly with increase of glycerol concentration up to ≈30% within gel dosimeters.
"Lifestyle medicine (LM) is an evidence-based therapeutic intervention delivered by clinicians trained and certified in this specialty to prevent, treat, and often reverse chronic disease". Eighty percent of the conditions primary care physicians routinely encounter in their offices, e.g., diabetes mellitus, hypertension, COPD, cardiovascular disease, have root causes in poor lifestyle choices such as smoking, insufficient sleep, being sedentary, or eating highly processed foods. Lifestyle is the foundation of most chronic disease management guidelines aimed at reducing morbidity and mortality. Studies have shown that changes in lifestyle can be achieved and link almost directly to reduction in risk for chronic illness. Primary care physicians are ideally positioned to incorporate LM into their practices. It is important to recognize and find solutions to the many barriers to implementing LM at the patient, physician, and system level. There is an urgent need to increase opportunities for practicing physicians to increase their knowledge and skills related to LM and include this in medical school and residency curricula. Many resources exist that can provide the necessary training for seasoned physicians and students/residents to become competent in practicing LM and address barriers to implementing LM. LM has the potential to revolutionize clinical practice by placing a greater emphasis on disease prevention and the role of healthy lifestyle behaviors in disease management.
This letter emphasizes the need to expand discussions on gut microbiome's role in inflammatory bowel disease (IBD) and colorectal cancer (CRC) by including the often-overlooked non-bacterial components of the human gut flora. It highlights how viral, fungal and archaeal inhabitants of the gut respond towards gut dys-biosis and contribute to disease progression. Viruses such as bacteriophages target certain bacterial species and modulate the immune system. Other viruses found associated include Epstein-Barr virus, human papillomavirus, John Cunningham virus, cytomegalovirus, and human herpes simplex virus type 6. Fungi such as Candida albicans and Malassezia contribute by forming tissue-invasive filaments and producing inflammatory cytokines, respectively. Archaea, mainly metha-nogens are also found altering the microbial fermentation pathways. This corres-pondence, thus underscores the significance of considering the pathological and physiological mechanisms of the entire spectrum of the gut microbiota to develop effective therapeutic interventions for both IBD and CRC.
The invention discloses a traditional Chinese medicine preparation used for treating skin ulcers. The preparation is prepared from the medicine materials of, by weight, 0.5-2 parts of golden thread, 0.5-2 parts of amur corktree bark, 1-3 parts of Chinese pulsatilla, 1-3 parts of purslane, 2-4 parts of weathered sodium sulfate, 1-3 parts of cortex pseudolaricis, and 0.5-2 parts of safflower. The traditional Chinese medicine preparation can be prepared into tablets, mixtures, granules, and capsules. When the preparation is used externally, heat clearing, dampness eliminating, blood cooling, detoxifying, swelling subsiding, and pain relieving functions are provided. The preparation is mainly used for treating various skin ulcers, and especially suitable to be used in treating varicose ulcer of lower extremity, traumatic ulcer, infective ulcer, and other diseases with main symptoms of local red swelling and exudation at skin wound surfaces. The invention also discloses preparation methods of the various preparation types.